Get started
Author

Juan Miguel Bergua Burgués

Observed names: J. M Bergua Burgues, J. M. Bergua Burgues, J.M. Bergua Burgues, Juan Bergua, Juan Miguel Bergua Burgues, Juan Miguel Bergüa Burgues, Juan Miguel M. Bergua Burgues, Juan Miguel Miguel Bergua Burgues
OpenAlex ID: A5032225567
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
2025 · Lorenzo Falchi, Marcel Nijland, et al. · The Lancet · 33
Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study
2023 · Jeffrey Lancet, Farhad Ravandi, et al. · Blood · 33
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
2021 · Hervé Tilly, Franck Morschhauser, et al. · Blood · 10
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML
2024 · Pau Montesinos, Rebeca Rodriguez-Veiga, et al. · Blood · 7
Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)
2018 · Joshua F Zeidner, Tara L Lin, et al. · Blood · 7
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
2022 · Sabine Kayser, David Martínez-Cuadrón, et al. · Haematologica · 6
PDF
Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry
2020 · Jorge Labrador, David Martínez-Cuadrón, et al. · Blood · 6
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.
2024 · Jeong A Kim, Uwe Hahn, et al. · Journal of Clinical Oncology · 5
PDF
S132: Updated Results of Ven-a-qui Study: a Phase 1-2 Trial to Assess the Safety and Efficacy of Triplets for Newly Diagnosed Unfit Aml Patients: Azacitidine or Low-dose Cytarabine With Venetoclax and Quizartinib
2023 · Juan Miguel Bergua Burgues, Rebeca Rodríguez-Veiga, et al. · HemaSphere · 5
Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
2022 · Alison R. Walker, Juan Miguel Bergua Burgues, et al. · Journal of Clinical Oncology · 5
Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.
2020 · Neha Mehta-Shah, Julio C. Chavez, et al. · Journal of Clinical Oncology · 4
Genetics and MRD for therapy allocation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia
2026 · Josep-Maria Ribera, Anna Torrent, et al. · Blood · 3
Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial
2025 · Claudia Sargas, Augustin Boudry, et al. · Blood · 3
PDF
FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients—efficacy and microbiologic safety
2023 · Ainhoa Fernández Moreno, Lucía Lavín-Alconero, et al. · Trials · 3
PDF
First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
2021 · David Belada, Katerina Kopeckova, et al. · Blood · 3
Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3
2025 · Umberto Vitolo, Johannes Duell, et al. · Blood · 2
158 | Epcore Dlbcl‐3: Fixed‐duration Epcoritamab Monotherapy in Older (≥ 75 Y), Anthracycline‐ineligible Patients With Previously Untreated Large B‐cell Lymphoma (lbcl)
2025 · D. Belada, M. Kwiatek, et al. · Hematological Oncology · 2
PDF
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry
2023 · David Martinez-Cuadron, Blanca Boluda, et al. · Blood · 2
A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase
2020 · David Belada, Grzegorz S. Nowakowski, et al. · Blood · 2
Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry
2020 · Pilar Martínez, Tomás Palanques Pastor, et al. · Blood · 2
Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial
2018 · Bruno Paiva, David Martínez-Cuadron, et al. · Blood · 2
Prognostic impact of variant allele frequency in intensively treated patients with NPM1 -mutated AML: a PETHEMA study
2026 · José Vicente Gil, Claudia Sargas, et al. · Blood · 1
Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study
2025 · Beatriz Martín Herreros, Irene Navarro Vicente, et al. · Blood · 1
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
2024 · Jonas S. Heitmann, Juliane S. Walz, et al. · Blood · 1
PDF
Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
2024 · Irene Navarro Vicente, Antonio Solana-Altabella, et al. · Blood · 1
Works count: 75
Citation count: 156
H-index: 6
I10-index: 3
Year
Topic
Type